Online inquiry

IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10646MR)

This product GTTS-WQ10646MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10646MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15834MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ1214MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ13465MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ13751MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ2888MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ4054MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ1594MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ10133MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LAG-525
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW